EGFR and non-small cell lung carcinoma: Although patients with NSCLC harboring EGFR-activating mutations exhibit high sensitivity to first-generation EGFR-tyrosine kinase inhibitors (TKIs), resistance often emerges within the first 9–14 months of therapy and is mediated primarily by the secondary T790M mutation6.